66 results about "Sodium tanshinone IIA sulfonate" patented technology

The persent invention relates to a sodium tanshinon IIA sulfonate glucose injection and its preparation method. Said injection contains (by wt%) 0.002-0.016% of sodium tanshinon IIA sulfonate, 5-25% of glucose, 0.05-0.2% of antioxidant and the rest is injection water. Said injection can obtain good therapeutic effect, and its preparation method is simple.

The invention relates to a refining method of tanshinone II sulfonate. The method comprises the following procedures, firstly the crude tanshinone II sulfonate to be purified is added into the mixture solution of the organic solvent and water, heated to 40 to 60 DEG C, agitated to dissolve and filtered to remove the insoluble particles; secondly, the filtrate is slowly decreased to the temperature of 0 to 30 DEG C and crystallized and filtered; thirdly tanshinone II sulfonate with high purity is obtained after the vacuum drying. The contents of tanshinone II sulfonate can reach 99.5 percent and the quality can meet the purity requirement of raw medicine for injection by HPLC analysis. The method of the invention has the advantages of simple method, easy operation, low refining cost and being suitable for the industrialized production.

This invention relates to a method for preparing high-purity sodium tanshionone IIA sulfonate, and preparations containing the compound. Determined by HPLC, the content of sodium tanshionone IIA sulfonate is higher than 96%, the total content of the related materials is lower than 10%, and the content of individual impurities is lower than 4.0%. The injection of high-purity sodium tanshionone IIA sulfonate can avoid the problems of flotation and precipitation of components. Besides, the compounds can also be manufactured into large-volume infusion and freeze-dried powder injection.

The invention relates to tanshinone IIA derivatives. The structure of the tanshinone IIA derivatives are carbonylated and acylated products of tanshinone IIA furan ring 2-position sulfonamide as show in a formula (I), wherein R is C1-6 alkyl, cycloalkyl, alkenyl, alkynyl, aryl and aromatic heterocycle and M is a metal ion such as a sodium salt. According to the compounds, on the basis that the activity and water solubility of sodium tanshinone IIA sulfonate are maintained, the acidity of the compounds is reduced; when sodium tanshinone IIA sulfonate is injected, the stimulation to patients is reduced and the stability of the compounds is improved.

The invention discloses a tanshinone IIA phosphoric acid derivative and synthesis and use thereof as a medicine for treatment. In particular, the present invention provides a novel derivative shown as a general formula (I) and a pharmaceutically acceptable salt thereof or a pharmaceutical composition containing the novel derivative shown as the general formula (I), and a method for preparing the novel derivative shown as the general formula (I). The invention also discloses use of the novel derivative, the pharmaceutically acceptable salt thereof or the pharmaceutical composition containing the novel derivative in preparation of medicines for treatment of coronary heart disease, angina, myocardial infarction, viral myocarditis, arrhythmia, cerebrovascular disease, hepatitis, pulmonary heart disease, bronchial asthma, cancer, kidney disease, eye disease, thromboangiitis obliterans, hypertension, fractures, burns, surgical operations or behcet ' s syndrome. On the basis of ensurance of the activity of tanshinone IIA, the novel derivative, the water solubility of the pharmaceutically acceptable salt thereof or the pharmaceutical composition containing the novel derivative can be improved. Compared with tanshinone IIA sodium sulfonate, the stability is improved, and because the acidity of the pharmaceutically acceptable salt thereof or the pharmaceutical composition containing the novel derivative is reduced obviously, injection stimulation can be avoided. All substituents of the general formula (I) are as defined in the specification.

The invention is a high performance liquidoid analytical method of tanshinone IIA sodium sulfonate which employs the reverse-phase gradient elution method, The proportion of organic phase and aqueous phase is 0-80:20-40 at 0 minute -8 to 20 minutes,the proportion of organic phase and aqueous phase is 80-95:5-20 at 8 minutes to 20 minutes -20 to 40 minutes. The invention can detect the tanshinone IIA, tanshinone I sodium sulfonate and other relative substance in tanshinone IIA sodium sulfonate at the same time, resolve the shortage of general liquid phase analysis, effectively control the quality of raw material of tanshinone IIA sodium sulfonate and its preparation, quickly and conveniently detect the relative substance of raw material of tanshinone IIA sodium sulfonate and its preparation.

The invention relates to a pharmaceutical composition of salvia miltiorrhiza bge extractive, and the use of the pharmaceutical composition. The pharmaceutical composition is formed by combining salvianolic acid A or salvianolic acid B with tanshinone IIA sodium sulfonate or combining salvianolic acid A and salvianolic acid B with tanshinone IIA or sodium tanshinone IIA sulfonate. The therapeutical effect on myocardial infarction of the pharmaceutical composition is better than that of each constituent used singly, and the pharmaceutical composition can better achieve the therapeutical effects of multiple ingredients and multiple target points of salvia multiorrhiza bge and is used for preparing medicine for treating cardio-cerebrovascular diseases. According to the conventional manufacturing technology of pharmaceutics, the pharmaceutical composition can be processed into tablets, capsules, granules, freeze-drying preparation for injection, or freeze-drying preparation or powder for injection of carboxylate of the pharmaceutical composition.

The invention relates to application of sodium tanshinone IIA sulfonate in preparation of medicines for treating acute or chronic diseases accompanied with increase of homocysteine in blood, alone oras an effective component. Vascular endothelial cells, myocardial cells, nerve cells and isolated blood vessel models are used to simulate the damage effect of the homocysteine on cardiovascular and cerebrovascular systems, it discovers that sodium tanshinone IIA sulfonate has a protection and / or treatment effect on the cardiovascular and cerebrovascular damages caused by the homocysteine, and theblank of protection and / or treatment medicines for resisting the cardiovascular and cerebrovascular damages caused by the homocysteine is filled up. The medicines provided by the invention are suitable for diseases causing abnormal increase of the homocysteine in the blood, can play a role in protecting and / or treating cardiovascular and cerebrovascular injuries caused by resisting the homocysteine only by reaching effective concentration in the blood, and provide a better choice for treating the cardiovascular and cerebrovascular injuries of diseases causing the increase of the homocysteinein the blood.

The invention discloses a novel green synthesis method of tanshinone IIA sodium sulfonate, which comprises the following step: directly carrying out a sulfonation reaction on tanshinone IIA by adopting safe, stable and cheap sodium hydrogen sulfate in the presence of a catalyst to obtain tanshinone IIA sodium sulfonate. Compared with the existing method, the method has the advantages that a targetproduct can be obtained through a one-step reaction; strong corrosive sulfonation reagents such as concentrated sulfuric acid and pyridine sulfur trioxide and a large amount of saturated salt water and sodium carbonate needed by subsequent salt forming are avoided. The method has the advantages that the production process is simple and convenient, the efficiency is high, and reagents can be recycled, so that the production cost of the tanshinone IIA sodium sulfonate is obviously reduced, the environmental pollution pressure is greatly relieved, and the method has a great industrial productionvalue.

The invention relates to a refining method of sodium tanshinone IIA sulfonate. The method comprises the following procedures, a) adding a crude sodium tanshinone IIA sulfonate to be purified into a mixture solution of an organic solvent and water, heating to 40 to 60 DEG C, agitating to dissolve and filtering to remove insoluble particles; b) slowly cooling the filtrate to the temperature of 0 to 30 DEG C and crystallizing and filtering; c) obtaining the sodium tanshinone IIA sulfonate with high purity after the decompression drying. The contents of the obtained sodium tanshinone IIA sulfonate can reach 99.5 percent and the quality can meet the purity requirement of a raw medicine for injection. The method of the invention is simple and is easy to operate with low refining cost, and is applicable for the industrialized production.